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Background: The existence of two distinct groups of tumors with different clinical characteristic is a remarkable
feature of transitional cell carcinomas (TCCs) of the bladder. More than 70% are low-grade (LG) non-infiltrating (NI)
cancers at diagnosis, but 60-80% of them recur at least one time and 10-20% progress in stage and grade. On the
other hand, about 20% of tumors show muscle invasion (IN) and have a poor prognosis with <50% survival after
5 years. This study focuses on the complexity of the bladder cancer genome, and for the first time to our
knowledge, on the possibility to compare genomic alterations of in vitro selected cancer stem-like cells (CSCs),
and their original biopsy in order to identify different genomic signature already present in the early stages of
tumorigenesis of LG and HG tumors.
Methods: We initially used conventional chromosome analysis on TCC biopsies with different histotypes (LG vs HG)
in order to detect rough differences between them. Then, we performed array comparative genomic hybridization
(aCGH) on 10 HG and 10 LG tumors providing an overview of copy number alterations (CNAs). Finally, we made a
comparison of the overall CNAs in 16 biopsies and their respective CSCs isolated from them.
Results: Our findings indicate that LG and HG bladder cancer differ with regard to their genomic profile even in
the early stage of tumorigenesis; moreover, we identified a subgroup of LG samples with a higher tendency to lose
genomic regions which could represent a more aggressive phenotype.
Conclusions: The outcomes not only provide valuable information to deeper studying TCC carcinogenesis, but also
could help in the clinic for diagnosis and prognosis of patients who will benefit from a more aggressive therapy.
Keywords: Transitional Cell Carcinoma, Array Comparative Genomic Hybridization, DNA copy number alterations,
cancer stem like-cellsBackground
Bladder cancer is the fourth most common cancer in men
and the eighth in women in both incidences and mortality
and over 90% of bladder tumors are transitional cell car-
cinomas (TCCs). The existence of two distinct groups of
tumors with different clinical features is a remarkable fea-
ture of TCC. More than 70% are in fact low-grade (LG)
non-infiltrating (NI) cancers at diagnosis, that can be* Correspondence: angela.bentivegna@unimib.it
†Equal contributors
1Department of Surgery and Translational Medicine, University of
Milan-Bicocca, via Cadore 48, 20052 Monza, Italy
Full list of author information is available at the end of the article
© 2014 Conconi et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.treated endoscopically by transurethral resection (TUR)
alone, recur at least once and 10-20% progress in stage
and grade. Thus repetitive and costly follow-up based on
urine cytology, cystoscopy and imaging studies of the
urinary tract is required, even if the prognosis is usually
good. On the other hand, about 20% of tumors show
muscle invasion (IN) at diagnosis and have a poor prog-
nosis with <50% survival after 5 years [1]. A model for at
least two major pathways has emerged based on the exist-
ence of these two distinct groups of lesions [2,3]. LG NI
tumors are generally characterized by constitutive activa-
tion of the receptor tyrosine kinase–Ras pathway, and they
have activating mutations in the proto-oncogene FGFR3l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pressor pathways of TP53, RB1 or PTEN were found in
muscle-invasive lesions [5,6]. Array comparative genomic
hybridization (aCGH) studies have been instrumental in
delineating genomic regions that are targeted by copy
number changes, called Copy Number Alterations (CNAs).
Several aCGH studies of bladder cancer have been pub-
lished to date and provide the identification of a number of
genomic regions of DNA amplification that contain known
or candidate oncogenes including cyclin D1 (CCND1) on
11q13 [7,8], ERBB2 on 17q21 [9], MDM2 on 12q14–q15
[10], and E2F3 on 6p22 [11]. Similarly, deletions of ge-
nomic regions containing tumor suppressor genes, such as
CDKN2A, DBC1 and TSC1 (at 9p21, 9q33 and 9q34, re-
spectively), PTEN on 10q23, RB1 on 13q14, and TP53 on
17p13 [12]. Some of these aberrations have been associated
with the pathological stage and/or outcome of bladder can-
cer. Several studies evidenced exclusive genomic alterations
in LG and HG tumors [13], with a significant increase in
CNAs and genomic instability with increasing stage/grade
and with outcome [14,15]. In addition, the over-representa-
tion of focal amplifications, such as at chromosome 6p22,
was significantly associated with HG IN tumors [16] and
recurrent cases [17].
Since it is currently believed that bladder cancer is de-
rived from a common cancer stem cell (CSC) likely de-
rived by transformation of urothelial cells of the basal
layer, bladder CSCs have been isolated based on basal
cell markers such as CD44. Nevertheless, in this way,
CSCs have only been identified in HG IN tumors
[18-21] suggesting that a distinct progenitor cell type ex-
ists for LG NI. A recent study of Dancik et al. provides
evidence of the existence of distinct progenitor cells in
NI and IN tumors, supporting new conceptual frame-
work for investigating and understanding bladder cancer
[22]. CSCs are responsible for treatment failure and can-
cer recurrence since they exhibit specific stem cells fea-
tures, such as growth as nonadherent spheres in a stem
cell medium, unlimited self-renewal, multipotency and
lineage-specific differentiation [23]. Understanding the
origins and supporting mechanisms of these cells and
their relation to the bulk population has a great rele-
vance for improving the knowledge of cancer pathogen-
esis and therapeutics [23].
In the first step of this study we performed conventional
chromosome analysis on TCC biopsies with different his-
totypes (LG vs HG) in order to detect rough differences
between them. We subsequently performed aCGH analysis
on another set of 20 biopsies to look for chromosomal im-
balances and smaller differences. In a second step, we
compared the global pattern of CNAs in 16 of these biop-
sies with the corresponding isolated CSCs in order to re-
veal specific genomic aberrations that would provide them
with growth advantages and a more aggressive phenotype.Methods
Ethics statement
This study was approved and founded by Direzione
Generale Sanità Regione Lombardia and presented by
General Director and ethic commitment of ICP Hospital
Bassini, Milan. Written informed consent was obtained
from the study participants before tissue collection.
Tumor specimens
45 tumor specimens were obtained by transurethral re-
section of the bladder (TURB) in a consecutive series of
patients newly diagnosed with TCCs at a single center.
Staging and grading were done according to the World
Health Organization Consensus Classification by a pa-
thologist [24]. They were distinguished in high or low
grade (HG or LG) and in muscle invasive or not (IN or
NI) (see Additional file 1: Table S1).
Cells’ isolation
CSCs were isolated from 35 biopsies following a pub-
lished protocol [25]. Briefly, biopsies were subjected to
mechanical and enzymatic digestion and the resulting
single cells were cultured in a specific medium with
20 ng/ml epidermal growth factor (EGF) and basic fibro-
blast growth factor (bFGF) (TebuBio, Rocky Hill, NJ,
USA). Cells were seeded at a low density (2×104 viable
cells/ml) in the absence of supplementary substrate or
adhesion factors and let grow for one week under stan-
dard culture conditions.
Conventional chromosome analysis
Biopsies were subjected to mechanical disruption and
incubated for 18-24 h with RPMI-1640 (Euroclone Spa,
Milano, Italy) supplemented with 20% FCS. Metaphase
chromosome spreads were prepared by direct technique
following an overnight colcemid treatment (0.1 μg⁄mL).
The fragments were incubated with hypotonic solution
with sodium citrate tribasic dihydrate (1%) for 30 minutes
at room temperature (RT), while in the same time, even-
tual cells which were in suspension were pelleted and
subjected to hypotonic treatment with 0.56% w/v KCl
for 20 minutes at RT. Then cells were fixed with 3:1
methanol:acetic acid. The chromosomes were QFQ-
banded using quinacrine mustard and slides were moun-
ted in McIlvaine buffer. The number of metaphases
depends on the quality of chromosome preparations.
The karyotype was defined following the guidelines of
the International System for Chromosome Nomenclature
2009 (ISCN 2009).
Fluorescence in situ hybridization (FISH)
Fluorescence in situ hybridization was carried out using
commercial probes: whole chromosome painting (wcp)
probe for chromosome Y (Cytocell, Cambridge, United
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CEP X Spectrum Green (Vysis, Abbott Molecular,
Abbott Park, Illinois, U.S.A.), or UroVysion bladder
cancer kit (Vysis, Wiesbaden, Germany), according to
the manufacturer's instructions. The procedures were
assessed according to the manufacturer’s protocol and a
minimum of 50 nuclei were evaluated. All digital images
were captured using a Leitz microscope (Leica DM
5000B) equipped with a charge coupled device (CCD)
camera and analyzed by means of Chromowin software
(Thesi Imaging, Milano, Italy).
DNA extraction for array comparative genomic
hybridization (aCGH)
Genomic DNA was extracted from fresh biopsies after en-
zymatic digestion with collagenase H (Roche, Mannheim,
Germany). Cells were harvested, washed with a saline
solution, digested with proteinase K (Roche, Mannheim,
Germany) and purified using phenol/chloroform (Carlo
Erba, Milan, Italy). In 16 cases the same procedure for
DNA extraction was applied to the isolated CSCs after
one week under culture conditions that favor stem cell
growth (see above).
Array comparative genomic hybridization (aCGH)
experiments
Sample preparation, slide hybridization, and analysis were
performed using SurePrint G3 Human CGH Microarray
8×60K (Agilent, Santa Clara, CA) according to the manu-
facturer’s instructions. Sex-matched commercial DNA
samples (Promega) were used as reference DNA during
aCGH. The arrays were scanned at 2-mm resolution using
Agilent microarray scanner and analyzed using Feature
Extraction v10.7 and Agilent Genomic Workbench v5.0
softwares. The Aberration Detection Method 2 (ADM2)
algorithm prompted by Genomic Workbench software
was used to compute and assist the identification of aber-
rations for a given sample (threshold = 5; log2 ratio = 0.3).
To calculate the estimated percentage of mosaicism we
used the formula determined by Cheung et al. [26].
Gene ontology analysis
To analyze which ontology classes were over- and
under-represented among the genes contained in gain
and loss regions detected by aCGH in both biopsies and
cancer stem-like cells, we used the GOstat software [27].
The GO terms in the output are linked to a visualization
tool for the GO hierarchy (AmiGO, the Gene Ontology
database, version 1.8).
Characteristics of the analyzed samples
In this study we collected 45 primary TCCs, six females
and 39 males. The mean age was 73.88 [SD = 12.9] years.
The tumors were low grade in 26 patients, and only onecase was infiltrating; 19 were high grade, 13 of which
were infiltrating (see Additional file 1: Table S1). We
were able to establish cultures of CSCs from 35 biopsies
applying our published protocol for the isolation and
characterization of CSCs from Bladder Cancer [25], be-
cause in 10 cases the tumor was of inadequate size for
processing, as specimens from TURB are generally very
small (less than 50% exceed one cm) [25]. Furthermore,
as the number of isolated cells was too low, in 19 cases
the cultures have died within a week. Additional file 1:
Table S1 and Additional file 2: Figure S1 summarize the
analysis carried out and the methods of this study. It
was not possible to perform all experiments on all sam-
ples, because of the small size of them. The first 5 sam-
ples were sacrificed in order to isolate and characterize
CSCs: we checked proliferation, self-renewal abilities
and positivity for several stem cell markers (Oct-3/4,
nestin, CD133), of the isolated cells after one week in
culture conditions that favor stem cell growth (data not
shown).
Results
Conventional chromosome analysis and FISH reveals
differences between LG and HG tumors
Conventional karyotype analysis was performed on 20
cases, but metaphases were achieved only in 13 cases
(65%) (see Table 1). Despite the low number of cases, in
4 out of 6 LG samples most of the cells have a number
of chromosomes which ranges from near-haploid (23 ±)
to near-diploid (46 ±), while in the remaining samples
it ranges from near-triploid (69 ±) to near-tetraploid
(92 ±). In HG samples a division in 2 groups was main-
tained: 3 out of 7 cases have a near-diploid (42.5 - 48)
median number of chromosomes, while the remaining
cases have a hypertriploid/hypotetraploid (72–83) me-
dian number. Moreover, there is a trend towards dis-
persion in the number of chromosomes per cell, moving
from LG to HG (Figure 1A). In addition, evidence for a
general chromatin instability and degeneration was
observed together with many different numerical and
structural aberrations, especially for Y chromosome
(Figure 1B).
We have also carried out an in-depth study of the Y
chromosome by FISH analysis using the WCPY probe
on interphase nuclei of 9 cases. Despite the presence of
a great heterogeneity, i.e. the percentage of cells and the
number of signals (see the graphic in Figure 2A), we evi-
denced a trend to the complete loss of Y chromosome in
two LG non-invasive cases (9 and 10); three HG samples
(17, 24 and 25) manifested the propensity to maintain
the Y chromosome, but with a slight trend to acquire
one additional copy (more evident for the non-invasive
case 17); two overlapped cases (11 and 23), with dif-
ferent grade and stage, show a tendency to two copies of
Table 1 Conventional chromosomal analysis







n± 2n± 3n± 4n± 5n± 6n± 7n±
6 LG NI 1 21 100
7 LG NI 1 46 100
11 LG NI 2 44-45 100
10 LG NI 13 27-162 78 80 7.7 7.7 61.5 15.4 7.7
9 LG NI 93 26-83 41 41 12.9 84.9 1.1 1.1
16 LG I 1 80 100
20 HG NI 13 30-118 46 45 7.7 61.5 15.4 7.7 7.7
17 HG NI 3 77-83 78 ND 66.7 33.3
19 HG NI 57 39-159 83 83 7 30 61.4 1.8
21 HG I 6 36-123 42.5 ND 83.3 16.7
25 HG I 14 46-121 73.5 70 7.1 78.6 14.3
23 HG I 12 21-73 48 ND 25 41.7 33.3
24 HG I 152 20-152 72 75 3.3 9.9 86.2 0.6
Summary of conventional karyotype analysis results.
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invasive cases) show a trend to acquire two or even
more copies of the chromosome; this propensity is not
found for the X chromosome (see Figure 2B).
aCGH analysis on tumor biopsies confirms more altered
genomes in HG tumors
We performed aCGH analysis on the subsequent 20
tumor biopsies, 10 HG and 10 LG (see Additional file 1:
Table S1), identifying a total of 495 aberrations. As ex-
pected, HG tumors were generally more affected than
LG: average of 40.3 aberrations per tumor in HG versus
9.2 per tumor in LG (Additional file 3: Table S2). In par-
ticular, 120 versus 55 were loss, 241 versus 25 were gain,
and 42 versus 12 were amplification. All chromosomes
harboured a spectrum of alterations in multiple tumors.
The chromosomes that had the fewest aberrations were
chromosomes 21 and 18 with 4 and 10 aberrations re-
spectively; most aberrations were found on chromosome
6 (n = 46). Other chromosomes with high aberrations
counts were chromosomes 1, 2, 9 and 11 with 37, 38, 34
and 32 alterations respectively. More detailed informa-
tion on all specific chromosomal regions altered either
by copy number gains or losses in tumor biopsies is pro-
vided in Additional file 4: Table S4.
Bladder cancer genomic aberrations: comparison
between biopsy samples and the respective CSCs
The most interesting aspect of this work is the compari-
son of the genomic profiles of 16 biopsies (6 HG and 10
LG) with their respective CSC subpopulations isolated
from them (see Material and Methods and Additional
file 1: Table S1). We analyzed by aCGH the genomic
profiles of CSC subpopulations evidencing a total of 614aberrations (Additional file 5: Table S3). Surprisingly,
HG tumors were less affected than LG tumors as the
average of aberrations was 16.83 in HG versus 51.3 in
LG. In particular, the largest imbalance between LG and
HG is in losses (average 46.6 per tumor LG versus 7 per
tumor HG, respectively). The chromosomes that had the
most losses were chromosomes 1, 2, 19 with 41, 35 and
35 losses, respectively, in LG tumors. More detailed in-
formation on all specific chromosomal regions altered
either by copy number gains or losses in CSC subpopu-
lations is provided in Additional file 6: Table S5.
Comparing the overall aberrations per chromosome of
biopsies with their respective isolated cells, we found a
trend reversal between HG and LG tumors because in
HG group the cells have a lower number of CNAs com-
pared to the initial biopsy, while in LG group it is the
exact opposite (Figure 3). In order to find shared aber-
rations between a specific biopsy and the respective iso-
lated cells, we compared the paired genomic profiles
(“biopsy” and “isolated cells”) for each sample. Overall,
there is a good overlapping between biopsies and iso-
lated cells (see Additional file 7: Table S6 A, B, C). Vali-
dation experiment using UroVysion FISH was performed
for the most frequent alteration, the loss of 9p21, location
of the P16 tumor suppressor gene, and also the most con-
served between biopsies and isolated cells (Additional file
8: Figure S2). Finally, considering the cases with more ab-
errations, three samples were HG tumors (38, 36, 45) with
18, 13 and 10 aberrations, respectively; among the LG
tumors, two samples (27, 35) have 13 and 9 aberrations,
respectively. On the basis of the large number of clustered
breakpoints at chromosome 6, the chromothripsis hy-
pothesis may be invoked in two tumors (36 and 37)
(Additional file 9: Figure S3). The chromothripsis
Figure 1 Conventional chromosome analysis. A) Distribution of chromosome number per cell in LG and HG samples. B) Examples of
chromatin and chromosome instability in different metaphases. Chromatin degeneration (a) and chromosome rearrangements: in particular,
rearrangements of chromosome Y (b), 12 (c), 4 (d) and 1 (e). Examples of metaphases with chromosome Y rearrangements: clonal rea in the
same metaphase (f, arrows) or clonal rea in different metaphases from the same patient (g, i). Example of different rea in the same metaphase (h).
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Figure 2 FISH analysis. A) Distribution of WCP Y probe signals on interphase nuclei of 9 cases. B) Examples of nuclei and metaphases with a
correct number of chr Y (a, case 25) and with polysomy of chr Y from different patients (b: case 23, c: case 21, d: case 24). Rearrangements of chr
Y highlighted by WCP probe on metaphase (e) and polysomy of chr Y identified by SRY probe (f, red), that is not found for the X chromosome
(f, green) in the same patient (case 19).
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somes and their reassembly into derivative chromo-
somes in a single catastrophic event [28]. Interestingly,
the same pattern of alterations were found both in
biopsy and in isolated cells of tumor 36, emphasizing
the earliness of this event (see Figure 4).
Gene ontology analysis confirms two different ways in LG
and HG tumors
We performed a gene ontology analysis using the GOstat
software in order to find statistically over-represented GO
terms within groups of genes included in CNAs evidenced
by aCGH. Additional file 10: Table S7 reported statistically
significant (p < 0.05) GO terms for each sample. The dif-
ferent colors refer to genes contained in gained regions
(red), or lost (green), or both (yellow). Two main classes
of GO terms are the most represented: transcription and
apoptosis.
For transcription a general statistically significant over-
representation emerged in biopsies, both in LG than inHG tumors, although in the latters it can be noted a
greater presence of red color corresponding to gained
genes. As regards CSCs, the over-representation of red
(gained genes) was confirmed in HG; conversely in LG
samples prevailed the green color (lost genes), except for
sample 34. It’s interesting to note that two tumors (27
and 32) showed a GO terms reversal in concomitance
with the passage from biopsy to CSCs, from red to green
color.
For apoptosis emerged a significant over-representation
for both gained and lost genes (yellow color) in HG biop-
sies and in the LG sample 30, while two LG biopsies (27
and 34) were found with over-representation for gained
genes and two others (26 and 33) for lost genes. Con-
versely, there was a clear division in CSCs: six samples
(one of which is HG) had a significant over-representation
for lost genes, while five tumors (one of which is LG) for
gained genes.
For the other ontology classes it was observed a very
intricate situation for biopsies, while in CSCs again
+0,5 
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B 
+0,5 
    -1,0 
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Figure 3 Summary of copy number analysis (CytoGenomics v2.0 software; Agilent). Low grade (LG) biopsies (A) and their correspondent
cell cultures (B); high grade (HG) biopsies (C) and their correspondent cell cultures (D). All the samples were analyzed using human 8 x 60 K CGH
microarrays (Agilent). The y-axis represents log2 ratio value. The x-axis represents the genomic position of probes with chromosome numbers
indicated. Significative gains (log2 ratio > +0.5) and losses (log2ratio < −1.0) are shown in red and green colors, respectively. Gray color represents
nonsignificant recurrence of aberrations.
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ples, whereas the red (gained genes) for HG samples.
Discussion
This study focuses on the complexity of the bladder can-
cer genome, and for the first time to our knowledge, on
the possibility to compare genomic alterations of in vitro
selected cancer stem-like cells and their original biopsy
in order to identify different genomic signature already
present in the early stages of tumorigenesis of LG and
HG tumors. Despite the low number of cases enrolled
and therefore, at the moment, the interpretation may be
only hypothetical, the findings of this study may assume
a very important significance to those with closely re-
lated research interest. Firstly, we performed a conven-
tional karyotype on 20 biopsies (11 LG and 9 HG) in
order to delineate the status of ploidy in bulk tumors.
Despite this technique is far from being innovative, weobserved that LG tumors generally have near diploid
metaphases, while HG tumors have a tendency to triploidy
with a greater dispersion in the number of chromosomes
per cell. Furthermore, we revealed that only two samples
out of nine, both non-invasive LG, show a strong tendency
to Y chromosome loss. Conversely, the others maintain or,
at most, show an opposite tendency to acquire multiple
copies of this chromosome. Although the number of cases
is very low, this observation is a little in contrast with a re-
cent study showing that Y chromosome losses are equally
frequent in urothelial bladder cancer of all grades and
stages [29]. Our data seem to agree with another study
that showed a significant association of Y polysomies with
HG invasive tumors [30]. The overall observations ob-
tained by conventional chromosomal analysis and FISH
have confirmed a greater aggressiveness of HG tumors
than LG ones; in addition, although a larger number of
cases must be studied, we believe that the involvement of
Figure 4 Example of chromosome 6 chromothripsis both in biopsy (left) and in isolated cells (right) of the same tumor (n. 36). The x-axis
represents log2 ratio value. Significative gains (log2 ratio > +0.5) and losses (log2ratio < −1.0) are shown as coloured regions.
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coincidence that men are more affected by this type of
cancer [31].
In this work we present a comprehensive catalog of
CNAs across 20 tumor fresh biopsies providing an over-
view of their common alterations. The overall data evi-
denced a general chromosomal instability, especially in
HG tumors, with a general CNAs ratio of 4:1 respect to
LG tumors, and a ratio of 10:1 considering only gains. A
previous study by HR-CGH analysis had reached the
same conclusion [13]. In addition, in the present work
we unveiled an opposite situation analyzing the genomic
profiles of CSCs, as in HG tumors they were less
affected than in LG tumors, with a general ratio of 1:3
(1:6 if we consider only the losses). To understand this
anomalous behavior it would be useful to compare the
genomic alterations of the original biopsy with their iso-
lated cells because this approach may focus on the alter-
ations most involved in tumorigenesis of TCCs. The
overview of CNAs per chromosome (Figure 3) evidences
a better conservation between cells and biopsies of HG
tumors than LG tumors, even if isolated cells of HG
group are less altered than their original biopsies while
the situation is reversed in LG group. In two HG sam-
ples the complex pattern of CNAs involving chromo-
some 6 is consistent with “a chromothripsis like event”.
Morrison et al. have recently reported the chromothrip-
sis phenomenon in muscle-invasive TCCs [32]. These
authors postulated that chromothripsis is related to adefective replication-licensing complex and that it could
lead to intratumoral mutational heterogeneity. However,
a recent work suggests that more stringent criteria must
be used to identify chromothripsis and that it cannot be
distinguished from other complex genomic rearrange-
ments [33]. According to these authors, great caution
should be exercised when labeling complex rearrange-
ments as chromothripsis from genome hybridization and
sequencing experiments. In our study we identified
several shared gain/amplifications in chromosome 6 bet-
ween the biopsy and the isolated cells of the same
tumor, providing evidence in favor of a non-progressive
mechanism.
The differences between HG and LG tumors also
emerged by GO analysis, especially for two functional
GO classes: transcription and apoptosis. Additional
file 10: Table S7 shows a preponderance of GO terms for
transcription class derived from gained genes of biopsies
and isolated cells of HG tumors. Although some LG tu-
mors exhibited a similar behavior (i.e. 34 sample), statis-
tical significance for these tumors is determined by lost
genes, especially in isolated cells where it has been
shown many lost regions. Similarly, GO terms for apop-
tosis class were derived from lost regions of isolated cells
of LG tumors, while the same GO terms were linked to
gained regions of isolated cells of HG tumors. Thanks to
the comparative analysis between biopsies and CSCs
isolated from them, we can speculate that the driving
forces of tumorigenesis are quite different in HG and
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Specifically, we confirmed a good correlation between
the total number of CNAs and genomic instability with
increasing stage and grade of the biopsy [15]. Moreover,
we found that CSCs isolated from LG biopsies accumu-
late a disproportionate number of genomic losses, so the
isolated cells would be much altered respect to their ori-
ginal biopsy. This phenomenon was not observed in HG
tumors, then it would not seem the result of purely
random alterations due to culture conditions, but to
essential characteristics which diversify the two types of
tumor. Furthermore, GO stat analysis and aCGH data
evidenced a subgroup of LG tumors where this paradox
seems to be more evident. It would be interesting to ver-
ify if this subgroup of LG tumors could have a more ag-
gressive potential and a greater propensity to progress
and invade.
Conclusions
In this study we provide not only an overview of changes
in the CNAs of HG vs LG tumors, but for the first time
to our knowledge we also make a comparison of the
overall CNAs in biopsies and CSCs isolated from them.
Our approach indicate that LG differ from HG regarding
their respective genomic profile also in the early stage of
tumorigenesis; moreover it has been identified a sub-
group of LG samples in which the tendency to loss of
genomic regions is significantly higher. These findings
provide valuable information to deeper study TCC car-
cinogenesis and may be applicable in the clinic for the
identification of patients who will benefit from a more
aggressive therapy.
Additional files
Additional file 1: Table S1. Clinic-pathologic characteristics of samples.
Histotype, grade and type of analysis are indicated.
Additional file 2: Figure S1. The two step strategy of analysis applied
in this study.
Additional file 3: Table S2. List of aberrations for each chromosome in
20 tumor biopsies.
Additional file 4: Table S4. Specific chromosomal regions altered
either by copy number gains or losses in tumor biopsies. Chromosomal
positions were in accordance with the Human Genome Browser – hg18
assembly (NCBI Build 36.1).
Additional file 5: Table S3. List of aberrations for each chromosome in
16 CSC subpopulations.
Additional file 6: Table S5. Specific chromosomal regions altered
either by copy number gains or losses in CSC subpopulations.
Chromosomal positions were in accordance with the Human Genome
Browser – hg18 assembly (NCBI Build 36.1).
Additional file 7: Table S6. Shared aberrations between biopsies and
CSC subpopulations.
Additional file 8: Figure S2. Validation experiment using UroVysion
FISH of the most common alteration (9p21 loss) evidenced by aCGH.
UroVysion consists of fluorescently labeled DNA probes to the
pericentromeric regions of chromosomes 3 (red), 7 (green), and 17 (aqua)and to the 9p21 band (gold) location of the P16 tumor suppressor gene. A-B)
complete loss of gold signals (9p21) in 27 and 38 samples; C) mosaic loss of
gold signals in case 39. See [34] for more details about UroVysion FISH.
Additional file 9: Figure S3. Chromosome 6 chromothripsis in sample
36 and 37.
Additional file 10: Table S7. Statistically significant (p < 0.05) GO terms
by GOstat software are reported for each sample distinguishing between
biopsies (left) and isolated cells (right). The different colors refer to genes
contained in gained regions (red), or lost (green), or both (yellow). Two
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